Assessment of Serum Lipid Profiles and High-sensitivity C-reactive Protein Among Patients Suffering from Rheumatoid Arthritis at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study

References

• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322. doi:10.1136/annrheumdis-2013-20462724550173
   PubMed Web of Science ®Google Scholar
• Ungurianu A, Margină D, Grădinaru D, et al. Lipoprotein redox status evaluation as a marker of cardiovascular disease risk in patients with inflammatory disease. Mol Med Rep. 2017;15(1):256–262. doi:10.3892/mmr.2016.597227909725
   PubMed Web of Science ®Google Scholar
• Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment–a prospective, controlled study. Arthritis Res Ther. 2006;8(3):R82. doi:10.1186/ar195216646989
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Eng J Med. 2011;365(23):2205–2219. doi:10.1056/NEJMra1004965
   PubMed Web of Science ®Google Scholar
• Filippin LI, Vercelino R, Marroni N, Xavier RM. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol. 2008;152(3):415–422. doi:10.1111/j.1365-2249.2008.03634.x18422737
   PubMed Web of Science ®Google Scholar
• van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006;8(5):R151. doi:10.1186/ar204516984661
   PubMed Web of Science ®Google Scholar
• Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24–38. doi:10.1373/clinchem.2007.09736018160725
   PubMed Web of Science ®Google Scholar
• Klingenberg R, Lüscher TF. Rheumatoid arthritis and coronary atherosclerosis: two cousins engaging in a dangerous liaison. Eur Heart J. 2015;36(48):3423. doi:10.1093/eurheartj/ehv48926443024
   PubMed Web of Science ®Google Scholar
• Nanchen D, Gencer B, Auer R, et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J. 2015;36(36):2438–2445. doi:10.1093/eurheartj/ehv28926142466
   PubMed Web of Science ®Google Scholar
• Baumer Y, McCurdy S, Weatherby TM, et al. Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis. Nat Commun. 2017;8(1):1129. doi:10.1038/s41467-017-01186-z29066718
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482–487. doi:10.1136/ard.2010.13587121216812
   PubMed Web of Science ®Google Scholar
• Parveen S, Jacob R, Rajasekhar L, Srinivasa C, Mohan IK. Serum lipid alterations in early rheumatoid arthritis patients on disease modifying anti rheumatoid therapy. Indian J Clin Biochem. 2017;32(1):26–32. doi:10.1007/s12291-016-0566-928149009
   PubMed Web of Science ®Google Scholar
• Smolen J, Breedveld F, Schiff M, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244–257. doi:10.1093/rheumatology/keg07212595618
   PubMed Web of Science ®Google Scholar
• Hensor EM, McKeigue P, Ling SF, et al. Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology. 2019;58(8):1400–1409. doi:10.1093/rheumatology/kez049
   PubMed Web of Science ®Google Scholar
• Fautrel B, Kirkham B, Pope JE, et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. J Clin Med. 2019;8(9):1394. doi:10.3390/jcm8091394
   PubMed Web of Science ®Google Scholar
• Peltola H, Laipio M, Siimes M. Quantitative C‐reactive protein (CRP) determined by an immunoturbidimetric method in rapid differential diagnosis of acute bacterial and viral diseases of children. Acta Pædiatrica. 1984;73(2):273–274. doi:10.1111/j.1651-2227.1984.tb09944.x
   Web of Science ®Google Scholar
• Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE. Complement activation in patients with rheumatoid arthritis mediated in part by C‐reactive protein. Arthritis Rheumatism. 2001;44(5):997–1002. doi:10.1002/1529-0131(200105)44:5<997::AID-ANR178>3.0.CO;2-C11352263
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheumatism. 1992;35(5):498–502. doi:10.1002/art.17803505021575785
   PubMed Web of Science ®Google Scholar
• Aletaha D, Maa J-F, Chen S, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(12):1609–1615. doi:10.1136/annrheumdis-2018-21491831434637
   PubMed Web of Science ®Google Scholar
• Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013;31(2):142. doi:10.1038/nbt.248723334450
   PubMed Web of Science ®Google Scholar
• McGill P. Rheumatoid arthritis in sub-Saharan Africa. Ann Rheum Dis. 1991;50(12):965. doi:10.1136/ard.50.12.9651768173
   PubMed Web of Science ®Google Scholar
• Bengtsson C, Nordmark B, Klareskog L, Lundberg I, Alfredsson L. Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2005;64(11):1588–1594. doi:10.1136/ard.2004.03166615843455
   PubMed Web of Science ®Google Scholar
• Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis. 1998;47(8):2.
   Google Scholar
• Chang PY, Yang CT, Cheng CH, Yu KH. Diagnostic performance of anti‐cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis. Int J Rheum Dis. 2016;19(9):880–886. doi:10.1111/1756-185X.1255225940989
   PubMed Web of Science ®Google Scholar
• Hashemzadeh K, Saghafi M, Khajedaluee M, Sahebari M. Synovial Anti Cyclic Citrullinated Peptide Antibodies in Comparison with Serum Antibodies in Early and Late Rheumatoid Arthritis. Fort J Rheumatol. 2020;2(02):067–073. doi:10.26502/fjr.26880019
   Google Scholar
• Song Y, Kang E. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2009;103(3):139–146. doi:10.1093/qjmed/hcp16519926660
   PubMed Web of Science ®Google Scholar
• Pearle A, Scanzello C, George S, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(5):516–523. doi:10.1016/j.joca.2006.10.01017157039
   PubMed Web of Science ®Google Scholar
• Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53(12):2143–2154. doi:10.1093/rheumatology/keu22424907149
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984–1998. Clin Chem. 2008;54(2):335–342. doi:10.1373/clinchem.2007.10027118156284
   PubMed Web of Science ®Google Scholar
• Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47(3):403–411. doi:10.1093/clinchem/47.3.40311238289
   PubMed Web of Science ®Google Scholar
• Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One. 2009;4(7):e6242. doi:10.1371/journal.pone.000624219606218
   PubMed Web of Science ®Google Scholar
• Gotto AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012;110(1):3A–14A. doi:10.1016/j.amjcard.2012.04.002
   Web of Science ®Google Scholar
• Ansari SK, Jaiswal G. Raised Lipid Profile in Rheumatoid Arthritis-A Risk for CVD.
   Google Scholar
• Galarraga B, Khan F, Kumar P, Pullar T, Belch J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology. 2008;47(12):1780–1784. doi:10.1093/rheumatology/ken38618854346
   PubMed Web of Science ®Google Scholar
• Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75(2):341–347. doi:10.1136/annrheumdis-2013-20498725609412
   PubMed Web of Science ®Google Scholar
• Zhou C, Cao J, Shang L, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis Markers. 2013;1:35.
   Google Scholar